Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology

NCT04365881 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10084

Last updated 2020-04-28

No results posted yet for this study

Summary

The present study of loneliness during the COVID-19-related NPIs is part of a larger project aiming to investigate psychological reactions and symptoms associated with the current and ongoing governmental initiatives in place in Norway.

The results will lead to a better understanding of the psychological effects on quarantine on the population and consequently will be relevant for the development of tailored prevention and intervention programs fit for pandemic crises.

Objectives Investigate the levels of loneliness in a general population during the strict social distancing government-initiated non-pharmacological interventions (NPIs) for the COVID-19 pandemic.

Investigate risk and resilience factors for loneliness and the associations between loneliness and psychopathology symptoms during the NPIs.

Aims Inform the general public, policy makers, scientists, and health practitioners about the associations of the NPIs with the mental health problem of loneliness and its potential effect on psychopathology.

Provide a foundation for policymakers and health-care professionals to employ interventions that protect the general public against increased psychological suffering and dysfunction during society's handling of pandemics.

Conditions

  • Loneliness, Worry, Rumination, Health Anxiety, Depression, Anxiety

Interventions

OTHER

Cross-sectional observational study

Survey

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER
  • Modum Bad

    lead OTHER

Principal Investigators

  • Omid V. E. Ebrahimi, Cand Psychol · University of Oslo and Modum Bad

  • Asle Hoffart, PhD · Modum Bad and University of Oslo

  • Sverre Urnes Johnson, PhD · University of Oslo and Modum Bad

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2020-04-07
Completion
2020-04-07

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04365881 on ClinicalTrials.gov